BioJapan 2019

Comprehensive quantification and identification of trace proteins is possible!

Exosomes are gaining attention as targets with new biomarkers, and there is a demand for high-precision analysis of the proteins contained in exosomes. When analyzing blood samples, it is necessary to identify extremely small amounts of target molecules that are only present in exosomes secreted from the disease site, among the overwhelming majority of exosomes derived from normal cells. For this purpose, proteomics analysis methods that allow for the identification of more proteins and quantitative comparisons between samples are the optimal means. In DIA proteome analysis, we conduct proteome analysis using the Data-independent acquisition (DIA) method, which is renowned for its analytical depth and quantitativeness, with the state-of-the-art mass spectrometer Q-Exactive HF-X (Thermo Fisher Scientific). This method allows for the observation of up to 8,000 types of proteins in a single analysis and enables quantitative comparisons of individual proteins between samples. This service is a one-stop service that consistently handles everything from sample preparation to DIA proteome analysis, so customers can obtain high-depth proteome analysis data simply by sending in their samples.

• Contract Analysis
• Analysis Services
• Other contract services

We will accurately produce antibodies using screening methods such as exosomes!

We offer a step-by-step "antibody production contract service" tailored to your needs. We select antibodies that recognize the three-dimensional structure of target proteins present on the membrane surface using exosomes expressing the target protein, among other methods.

• Other contract services

You can directly quantify exosomes from blood samples and cell culture supernatants!

These are three types of products for the relative quantification of exosomes containing CD9, CD63, or CD81 molecules. - CD9/CD9 Exosome ELISA Kit - CD63/CD63 Exosome ELISA Kit - CD81/CD81 Exosome ELISA Kit Features: - Exosomes contained in blood samples or cell culture supernatants (serum-free) can be directly quantified. - No special equipment is required; measurements can be made with a standard plate reader. - Instead of using exosomes themselves, which lack storage stability as standard reagents, stability and reproducibility are ensured by using standard beads with a particle size of 200 nm that are coated with CD9 or CD63. - Relative quantification of each sample is possible by correcting with CD9, CD63, or CD81 standard beads that mimic exosome structures. - Exosomes are captured using solid-phase CD9, CD63, or CD81 antibodies, and detected with HRP-labeled CD9, CD63, or CD81 antibodies.

• others

We provide total support for exosome ELISA measurements and more.

We offer a contract service for the production of exosome detection tools that express and purify proteins in animal cells as an immunogen for antibodies against exosome surface markers. We provide comprehensive support for research on exosome detection methods, focusing on the production of recombinant proteins, the creation of monoclonal antibodies, the establishment of ELISA measurement systems, and exosome ELISA measurements. 【Service Details】 ■ Production of recombinant proteins ■ Creation of monoclonal antibodies against exosome surface markers ■ Establishment of ELISA measurement systems ■ Exosome ELISA measurements *For more details, please download the PDF or feel free to contact us.

• Other contract services

Although I have heard that verification efficiency at the RTL stage improves with verification methodologies using SystemVerilog such as UVM, many designers may not fully understand what can be done with SystemVerilog and how to use it. In this seminar, we will introduce the basic functions and usefulness of SystemVerilog verification using a sample design. 1. Design Overview 2. UART Test Environment 3. Assertions (SVA & PSL) 4. Functional Coverage 5. Random Test Bench 6. DPI-C

The RTCA/DO-254 guidance recommends that applicants define and implement HDL coding standards. This work begins with a planning process that includes the definition of the standard, how it will be implemented, and, if the process is automated, the evaluation methods for tools or results. A key issue is that the guidance does not have clearly defined formal standards, leading to questions about how to conduct a detailed review of HDL code. In this webinar, we will demonstrate the use of ALINT-PRO to enforce coding standards and highlight the benefits of streamlining the overall design review to meet the objectives of DO-254.

[Speaker] Takahiro Tachikawa, President of International University and Professor at the Graduate School of International Management [Key Lecture Content] In February of this year, the 7th Energy Basic Plan was approved by the Cabinet. What is the essence of this plan that the media and others do not convey? How will this plan impact the development and social implementation of hydrogen, ammonia, and next-generation fuels (synthetic methane, synthetic liquid fuels, green LP gas, etc.)? This lecture will delve into these points. In particular, it will focus on the content of the risk scenario, which is viewed as the main scenario among stakeholders in the energy industry, and the newly defined role of natural gas as an "important energy source even after achieving carbon neutrality." [Lecture Items] 1. The 7th Energy Basic Plan 2. Hydrogen 3. Ammonia 4. Synthetic Fuels 5. Risk Scenario 6. Natural Gas Shift 7. Q&A / Business Card Exchange

[Lecturer] Professor Shiro Kawabata, Faculty of Science and Technology, Hosei University [Key Lecture Content] Prime Minister Ishiba has positioned 2025 as the inaugural year for the industrialization of quantum technology and has indicated a policy to strengthen support for the industrialization of quantum technology. Additionally, at the G7 Summit held in Canada in June 2025, a joint statement titled "Joint Statement on the Future of Quantum Technology," focusing on quantum technology centered around quantum computers, was adopted. Quantum computers are computers that utilize principles of quantum mechanics, such as superposition and quantum entanglement, for information processing. By using quantum computers, it becomes possible to solve several mathematical problems, such as factorization, machine learning, quantum chemistry calculations, finance, and linear simultaneous equations, exponentially faster compared to classical computers. As a result, major global corporations and startups are globally expanding their development and business in quantum computer hardware and software. This seminar will introduce the basics of quantum computers, the latest research and development trends, business trends, technical challenges, and future prospects.

[Speaker] Shintaro Kobayashi, Group Manager, ICT and Content Industry Consulting Department, Nomura Research Institute, Ltd. [Key Lecture Content] The Personal Information Protection Law is undergoing fundamental changes to promote AI development. The Personal Information Protection Commission has proposed a shift towards a risk-based system where companies voluntarily address risks. A key feature of this new system is the establishment of a framework that allows the use of personal information for AI development without the need for individual consent. In this lecture, based on the policy of legal reform, we will carefully explain the points for advancing data utilization by leveraging the legal benefits of the new system, as well as how to establish privacy governance that should drive these efforts, incorporating specific initiatives and examples of solutions. [Lecture Items] 1. Trends in the amendment of the Personal Information Protection Law 2. Practical methods for utilizing personal information without individual consent 3. PETs for safely utilizing AI 4. Achieving governance efficiency and sophistication through AI 5. Q&A / Business card exchange